Register entry
- Registered sites
- 0
- Active NDC listings
- 11
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
1111 active NDC listings: 11 human prescription drug. By marketing category: ANDA 11.
| Dosage form | NDCs |
|---|---|
| tablet | 8 |
| capsule | 3 |
| Route | NDCs |
|---|---|
| oral | 11 |
| Labeller name on the listing | NDCs |
|---|---|
| gsms, incorporated | 11 |
Catalogue
Marketed products
11| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | tablet, oral | 51407-950ANDA |
| Amlodipine Besylate | Amlodipine Besylate | tablet, oral | 51407-951ANDA |
| LISINOPRIL and HYDROCHLOROTHIAZIDE | LISINOPRIL and HYDROCHLOROTHIAZIDE | tablet, oral | 51407-564ANDA |
| LISINOPRIL and HYDROCHLOROTHIAZIDE | LISINOPRIL and HYDROCHLOROTHIAZIDE | tablet, oral | 51407-565ANDA |
| LISINOPRIL and HYDROCHLOROTHIAZIDE | LISINOPRIL and HYDROCHLOROTHIAZIDE | tablet, oral | 51407-566ANDA |
| PIOGLITAZONE HYDROCHLORIDE | PIOGLITAZONE HYDROCHLORIDE | tablet, oral | 84677-026ANDA |
| PIOGLITAZONE HYDROCHLORIDE | PIOGLITAZONE HYDROCHLORIDE | tablet, oral | 84677-027ANDA |
| PIOGLITAZONE HYDROCHLORIDE | PIOGLITAZONE HYDROCHLORIDE | tablet, oral | 84677-028ANDA |
| Ramipril | Ramipril | capsule, oral | 51407-707ANDA |
| Ramipril | Ramipril | capsule, oral | 51407-708ANDA |
| Ramipril | Ramipril | capsule, oral | 51407-709ANDA |
Enquiry
Common questions
- Is GSMS, Incorporated FDA approved?
- GSMS, Incorporated holds no registered establishment of its own; 11 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does GSMS, Incorporated make?
- 11 products are listed under GSMS, Incorporated in the openFDA NDC Directory, most often as tablet; capsule. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.